XML 34 R17.htm IDEA: XBRL DOCUMENT v3.25.2
Balance Sheet and Other Details
 12 Months Ended
Jul. 26, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet and Other Details Balance Sheet and Other Details
The following tables provide details of selected balance sheet and other items (in millions, except percentages):
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
July 26, 2025July 27, 2024
Cash and cash equivalents$8,346 $7,508 
Restricted cash and restricted cash equivalents included in other current assets564 765 
Restricted cash and restricted cash equivalents included in other assets— 569 
Total$8,910 $8,842 
Our restricted cash and restricted cash equivalents are funds primarily related to contractual obligations with suppliers.
Inventories
July 26, 2025July 27, 2024
Raw materials$1,744 $2,039 
Work in process261 83 
Finished goods933 1,027 
Service-related spares220 216 
Demonstration systems6 8 
Total$3,164 $3,373 
Property and Equipment, Net
July 26, 2025July 27, 2024
Gross property and equipment:
Land, buildings, and building and leasehold improvements$4,045 $4,247 
Production, engineering, computer and other equipment and related software5,178 5,160 
Operating lease assets51 115 
Furniture, fixtures and other316 351 
Total gross property and equipment9,590 9,873 
Less: accumulated depreciation and amortization(7,477)(7,783)
Total$2,113 $2,090 
Remaining Performance Obligations (RPO)
July 26, 2025July 27, 2024
Product$21,572 $20,055 
Services21,961 20,993 
Total$43,533 $41,048 
Short-term RPO$21,723 $20,882 
Long-term RPO21,810 20,166 
Total$43,533 $41,048 
Amount to be recognized as revenue over the next 12 months
50 %51 %
Deferred revenue$28,779 $28,475 
Unbilled contract revenue14,754 12,573 
Total$43,533 $41,048 
Unbilled contract revenue represents noncancelable contracts for which we have not invoiced, have an obligation to perform, and revenue has not yet been recognized in the financial statements.
Deferred Revenue
July 26, 2025July 27, 2024
Product$13,490 $13,219 
Services15,289 15,256 
Total$28,779 $28,475 
Reported as:
Current$16,416 $16,249 
Noncurrent12,363 12,226 
Total$28,779 $28,475 
Transition Tax Payable
Our income tax payable associated with the one-time U.S. transition tax on accumulated earnings for foreign subsidiaries as a result of the Tax Act is as follows:
July 26, 2025July 27, 2024
Current$1,595 $1,819 
Noncurrent— 2,273 
Total$1,595 $4,092 
Our remaining transition tax payable as of July 26, 2025 has been reduced to reflect the transition tax benefit of the U.S. Tax Court opinion in Varian Medical Systems, Inc. v. Commissioner. See Note 18.